<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04565574</url>
  </required_header>
  <id_info>
    <org_study_id>E7090-J081-003</org_study_id>
    <nct_id>NCT04565574</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants</brief_title>
  <official_title>An Open-Label, Single-Dose Study to Assess the Effect of Food Intake and Drug-Drug Interactions of E7090 When Co-administered With Rabeprazole (Gastric Acid-Reducing Agent), or Rifampin (Strong CYP3A Inducer) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will have three parts: Part A, Part B, and Part C. The primary purpose of Part A&#xD;
      is to evaluate the effect of food on the rate and extent of E7090 absorption following single&#xD;
      oral doses of E7090 in healthy participants, Part B is to evaluate the effects of rabeprazole&#xD;
      (a gastric acid-reducing agent) on the rate and extent of E7090 absorption following single&#xD;
      oral doses of E7090 in healthy participants, Part C is to evaluate the effects of rifampin (a&#xD;
      strong Cytochrome P450 3A [CYP3A] inducer) on pharmacokinetics (PK) of single oral doses of&#xD;
      E7090 in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 16, 2020</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration of E7090</measure>
    <time_frame>0-144 hours post-dose following E7090 administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t): Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration of E7090</measure>
    <time_frame>0-144 hours post-dose following E7090 administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf): Area Under the Concentration-time Curve From Zero (Pre-dose) Extrapolated to Infinite Time of E7090</measure>
    <time_frame>0-144 hours post-dose following E7090 administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) of E7090</measure>
    <time_frame>0-144 hours post-dose following E7090 administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-72Hours): Area Under the Plasma Concentration Versus Time Curve from Time 0 to 72 Hours of E7090</measure>
    <time_frame>0-144 hours post-dose following E7090 administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2: Terminal Half-life of E7090</measure>
    <time_frame>0-144 hours post-dose following E7090 administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F: Apparent Total Body Clearance of E7090</measure>
    <time_frame>0-144 hours post-dose following E7090 administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F: Apparent Volume of Distribution at Terminal Phase of E7090</measure>
    <time_frame>0-144 hours post-dose following E7090 administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC Metabolite (M) Ratio: Ratio of AUC(0-inf) of M2 to AUC(0-inf) of E7090</measure>
    <time_frame>0-144 hours post-dose following E7090 administration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Part A: E7090 35 mg (Fasted + Fed + Fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive E7090 35 milligram (mg) tablet, orally on Day 1 of Treatment Period 1 in fasted state, followed by E7090 35 mg tablet, orally on Day 1 of Treatment Period 2 in fed state (high-fat meal). A wash out period of 5 days will be maintained between Treatment Periods 1 and 2. Further participant will receive E7090 35 mg tablet, orally on Day 1 of Treatment Period 3 in fed state (low-fat meal).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: E7090 35 mg (Fed + Fasted + Fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive E7090 35 mg tablet, orally on Day 1 of Treatment Period 1 in fed state (high-fat meal), followed by E7090 35 mg tablet, orally on Day 1 of Treatment Period 2 in fasted state. A wash out period of 5 days will be maintained between Treatment Periods 1 and 2. Further participant will receive E7090 35 mg tablet, orally on Day 1 of Treatment Period 3 in fed state (low-fat meal).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: E7090 35 mg + Rabeprazole 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive E7090 35 mg tablet, orally on Day 1 in fasted state, followed by a wash out period of 5 days, further followed by rabeprazole 20 mg tablets, orally, once daily on Days 7 to 10, and then followed by E7090 35 mg tablet and rabeprazole 20 mg tablets, orally on Day 11 in fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: E7090 35 mg + Rifampin 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive E7090 35 mg tablet, orally on Day 1 in fasted state, followed by a wash out period of 5 days, further followed by rifampin 600 mg capsules, orally, once daily on Days 7 to 12, then followed by E7090 35 mg tablet and rifampin 600 mg capsules, orally on Day 13 in fasted state, and then by rifampin 600 mg capsules, orally, once daily on Days 14 to 18.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E7090</intervention_name>
    <description>Oral tablet.</description>
    <arm_group_label>Part A: E7090 35 mg (Fasted + Fed + Fed)</arm_group_label>
    <arm_group_label>Part A: E7090 35 mg (Fed + Fasted + Fed)</arm_group_label>
    <arm_group_label>Part B: E7090 35 mg + Rabeprazole 20 mg</arm_group_label>
    <arm_group_label>Part C: E7090 35 mg + Rifampin 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole 20 mg</intervention_name>
    <description>Rabeprazole 20 mg (2 tablets, each of 10 mg) oral tablet.</description>
    <arm_group_label>Part B: E7090 35 mg + Rabeprazole 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin 600 mg</intervention_name>
    <description>Rifampin 600 mg (4 capsules, each of 150 mg) oral capsule.</description>
    <arm_group_label>Part C: E7090 35 mg + Rifampin 600 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants who meet all of the following criteria will be eligible for participation in&#xD;
        the study&#xD;
&#xD;
        1. Body mass index (BMI) between 18.5 to 25.0 kilogram per square meter (kg/m^2),&#xD;
        inclusive, at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants who meet any of the following criteria will be excluded from this study:&#xD;
&#xD;
          1. Following ocular disorders&#xD;
&#xD;
               1. Current evidence of Grade 2 or higher corneal disorder&#xD;
&#xD;
               2. Current evidence of active macular disorder (example, age-related macular&#xD;
                  degeneration, central serous chorioretinal disease)&#xD;
&#xD;
          2. Any clinically abnormal symptom or organ impairment found by medical history at&#xD;
             screening, and physical examinations, vital signs, electrocardiogram (ECG) finding, or&#xD;
             laboratory test results that require medical treatment at screening&#xD;
&#xD;
          3. A prolonged QT/QTc interval (QT interval with Fridericia's correction [QTcF] greater&#xD;
             than [&gt;] 480 millisecond [ms]) demonstrated on ECG at screening or baseline&#xD;
&#xD;
          4. Known history of food allergies or presently experiencing significant seasonal or&#xD;
             perennial allergy at screening&#xD;
&#xD;
          5. Known history of allergies or reactions to rabeprazole or rifampin or known&#xD;
             anaphylactic reaction to any drugs at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eisai trial site #1</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokoyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>E7090</keyword>
  <keyword>Food-effect</keyword>
  <keyword>Drug-drug Interactions</keyword>
  <keyword>Rabeprazole</keyword>
  <keyword>Rifampin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

